Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (September 2025)
40 slides from Alcidion's investor presentation, Sep 15, 2025
Slide 1: Investor Roadshow Presentation
15 September 2025 Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 Investor Roadshow Presentation Melbourne, Victoria | Alcidion Group Limited (ASX: ALC) (‘Alcidion’) Alcidion will be undertaking a series of meetings as part of an investor roadshow in Sydney on September 16 and 17 usi
Slide 2: Post FY25 Results Investor Roadshow and Growth Strategy Presentation
For personal use only Post FY25 Results Investor Roadshow and Growth Strategy Presentation September 2025
Slide 3: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 any change in expectations in relation to any such statements or any change in events, conditions or circumstances 410 (referred to as “Alcidion” or “Company”). This Document is
Slide 4: Snapshot
For personal use only 01. Snapshot
Slide 5: Investment Highlights
Investment Highlights Entering FY26 with significant momentum following a record FY25 and an established growth strategy underpinned by multiple drivers For personal use only Mission-critical health High quality, diversified and Attractive unit economics with Capital light business model informatics
Slide 6: Company Overview
Company Overview A leading global health informatics platform modernising legacy health systems at scale For personal use only 400+ 100+ 50k+ Global health informatics platform enhancing and replacing outdated, manual and legacy systems to meet modern day demands in healthcare. Hospitals Healthcare
Slide 7: FY25 – Financial Highlights
FY25 – Financial Highlights Record year across all key financial metrics For personal use only $40.8M $28.5M $73.8M $5.1M $5.8M FY25 revenue ARR1 (as at 30 Jun-25) FY25 new & renewal TCV Underlying EBITDA3 Operating Cashflow positive Up 10% on pcp1 Up 31% on 30 Jun-24 Up 109% on pcp Up $8.5M Vs. ($3
Slide 8: Revenue Dashboard
Revenue Dashboard Sustainable growth underpinned by long-term, contracted and high-quality recurring revenue For personal use only 40.4 40.8 37.1 H1 vs H2 34.4 21.4 23.1 Geographical Revenue 25.9 21.5 18.0 Split (%) 37% Split ($M) 14.8 $40.8M 19.0 19.1 17.6 Total UK ANZ 63% 12.9 11.1 FY21 FY22 FY23
Slide 9: Strong Global Footprint
Strong Global Footprint Growing global operations diversified across attractive target markets For personal use only 108 Health Services Global footprint across the UK, Australia and NZ. 10 Health Systems 100+ clinical system 447 Hospitals implementations. Canada Exploring New Markets 11 Health Syst
Slide 10: Market Drivers
Market Drivers Modern clinician needs and improved patient outcomes driving the digitisation of outdated, legacy systems For personal use only Transition to digital Operating efficiency Increasing demand Increasing industry and workflow for seamless clinical support & funding solutions Shift towards
Slide 11: Core Technology
For personal use only Core 02. Technology
Slide 12: What is Miya Precision?
What is Miya Precision? An unrivalled clinician and administration platform For personal use only Designed for AI Miya Precision has been designed for AI, enabling data consolidation to deliver insights to clinicians, whilst maintaining patient data security Digital Clinical Workflow Operate in Real
Slide 13: Smarter Solutions for Clinicians
Smarter Solutions for Clinicians Meeting the daily needs of clinicians, by clinicians Solutions For personal use only Powering Smarter Care Patient Flow Emergency Modular EPR Virtual Care Integrated At the core of Alcidion’s solutions & Command Emergency Modular cloud- Virtual care and Care Record i
Slide 14: Patient Journey with Miya Precision
Patient Journey with Miya Precison A value proposition at every point of care For personal use only 8. Miya Record 14. Miya Command • A single, longitudinal view of a patient’s healthcare • Real-time access to 1. Miya Emergency 7. Smartpage journey across providers consolidated data • Effective care
Slide 15: Competitive Advantage
Competitive Advantage Cloud based, flexible and intuitive customer-centric design Incumbents For personal use only Class Leading User Interface • Designed without the clinician in mind ✓ Widely recognised for useability in clinical settings • Rigid workflows with limited scope for customisation ✓ Hi
Slide 16: Business Model
For personal use only Model 03. Business
Slide 17: Our Revenue Model
Our Revenue Model Long-term contracted recurring revenue underpin sustainable and incrementally higher margin growth For personal use only Products >95%1 Technical Services <5%1 Core Offering Key Product / Data analytics, Integration, Services interoperability & technical design Revenue Implementati
Slide 18: Delivering Tangible Outcomes
For personal use only 04. Delivering Tangible Outcomes
Slide 19: Case Study: Alfred Health
Case Study: Alfred Health Independent Study on Miya Precision Benefits In 2023, Alfred Health introduced electronic patient journey boards (EPJBs) to 38 inpatient wards at The Alfred, Caufield and Sandringham hospitals. As part of the deployment, the Digital Health CRC & Monash University were engag
Slide 20: Case Studies
Case Studies Driving real-world tangible outcomes For personal use only 60 mins reduction in admin burden per 76% Reduction in cardiac arrests 40% reduction in time to take observations clinician per shift NHS Fife Basildon and Thurrock University Hospitals South Tees Hospitals NHS Foundation Trust
Slide 21: FY25 – New customer wins and increasing share of wallet
For personal use only 05. FY25 – New customer wins and increasing share of wallet
Slide 22: EPR Validation: North Cumbria
EPR Validation: North Cumbria Signed contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC) for new EPR platform solution For personal use only Key Contract Terms Contract Signed - Overview › Selected following a competitive tender process › Deploy Miya Precision encompassing full s
Slide 23: Notable Extension / Expansion Wins
Notable Extension / Expansion Wins Greater share of customer spend from increased TCV for existing customers For personal use only NT Health (AUS) Several PCS customers (UK) › Builds upon existing 9+ year relationship PCS › Extended several PCS customers (product name for Silverlink) for between 1-3
Slide 24: Successful Deployments in FY25
Successful Deployments in FY25 Product Implementation and technical service delivery have always been a strength of the Alcidion business For personal use only Hume Rural Health Alliance (AUS) Hampshire Hospitals NHS Foundation Trust › First site went ‘live’ in late Oct-24 › First deployment of Miya
Slide 25: Notable New Contract Wins
Notable New Contract Wins New contracts reinforce modular strategy, catering to needs of customers as they enhance their digital maturity For personal use only Hume Rural Health Alliance (AUS) Hywel Dda (Wales) › Miya Precision deployed as an enterprise › Miya Precision – Patient Flow, Observations
Slide 26: Land and Expand Strategy Driving TCV Uplift
Land and Expand Strategy Driving TCV Uplift Delivering tangible examples of strategies success… For personal use only Hume (Aust.) North Cumbria (UK) South Tees (UK) NT Health › Q1’25 – New contract covering 15 › Q3’25 – Milestone 10-year contract › Q2’20 - 5 years for several Miya › Extended to inc
Slide 27: Medium Term Growth Strategy and Outlook
For personal use only 06. Medium Term Growth Strategy and Outlook
Slide 28: Growth Pillars Support a Global Platform
Growth Pillars Support a Global Platform Multi-focus approach combining growth within existing customers, expansion in existing territories and attractive new markets and geographies For personal use only Organic Growth 1 Scale Existing Markets 2 Evolve Product Functionality 3 Expand into New Geogra
Slide 29: Scale in Existing Markets
Scale in Existing Markets Recent success in Australia highlights the material opportunity still existing in Australia which is complemented by larger UK opportunities For personal use only Australia UK & NHS markets Patient Flow England › Reduce incidence of bed blockage with effective patient flow
Slide 30: Evolve Product Functionality
Evolve Product Functionality Bringing generative AI to healthcare For personal use only Advanced technologies have always been part of the Miya Precision platform. Generative AI enables us to bring these capabilities into the clinical user interface, eliminating repetitive tasks & streamlining the c
Slide 31: Expand into New Geographies
Expand into New Geographies Priority targets selected based on highly attractive risk / reward profile with smaller investment required to gain market entry For personal use only Canada Middle East (Saudi Arabia, UAE) Win and Build Entry via Pilot Partner Steps taken to date: Steps taken to date: ›
Slide 32: Market Adjacencies
Market Adjacencies Interoperability and flexibility of platform architecture enables Miya to address critical patient challenges outside of acute setting For personal use only Aged Care Community Care (Home Care, NDIS) Reviewing ability to extend functionality of Miya Precision Similar to Aged Care,
Slide 33: Outlook
Outlook Momentum continuing into FY26 underpinned by high contracted revenue coupled with maturing pipeline of expansion & new opportunities For personal use only As of 30 June 2025, contracted & Targeting to be FY26 EBITDA positive Started market testing, partner renewal revenue to be recognised in
Slide 34: Corporate Snapshot
Corporate Snapshot ASX:ALC Trading Information ASX:ALC Share Price History For personal use only Share Price (12 September 2025) $0.091 $0.14 18m Volume Share Price ($) Volume $0.13 12-month Low / High $0.052 - $0.125 $0.12 Share Price 16m $0.11 12-month average daily liquidity ($) $107k 14m $0.10 1
Slide 35: Alcidion Board – Deep Healthtech Expertise
Alcidion Board – Deep Healthtech Expertise For personal use only Rebecca Wilson Kate Quirke Daniel Sharp Andrew Way William Smart Non-executive Chair Group Managing Director/ Non-executive Director Non-executive Director Non-executive Director Chief Executive Officer Experienced company director wit
Slide 36: Appendix
For personal use only 07. Appendix
Slide 37: Profit & Loss
Profit & Loss Record Revenue and Underlying EBITDA; underpinned by growth in ARR For personal use only Profit & loss (A$000) FY24 FY25 % Change 1 › Annual recurring product revenue (M&S + Annual Licenses) in FY25 reflects Recurring only partial contribution from new customers won during FY25 Product
Slide 38: Balance Sheet
Balance Sheet Significant balance sheet flexibility to pursue growth opportunities For personal use only Balance sheet ($000) FY24 FY25 Cash & cash equivalents 1 11,798 17,697 1 › $17.7m cash and no debt as of 30 June 2025 Trade & other receivables 5,214 3,680 Other assets 1,527 2,310 Current assets
Slide 39: Cashflow
Cashflow For personal use only Cash flow ($000) FY24 FY25 › Cash receipts materially exceeding revenue largely driven by inclusion Receipts from customers 1 43,881 50,858 1 Payments to suppliers & employees (50,831) (45,162) of relevant jurisdiction tax (i.e.. 10% GST in Australian and 20% VAT in In
Slide 40: For personal use only
For personal use only
Alcidion Group — Investor Presentation (September 2025) on 6ix